Christopher Frankenfield

Christopher Frankenfield is recorded as COO at Xilio Therapeutics, Inc. (XLO) since August 3, 2023. Xilio Therapeutics, Inc. reported in an 8-K filed August 3, 2023 that Christopher Frankenfield was appointed Chief Operating Officer, effective August 3, 2023. The proxy statement of Xilio Therapeutics, Inc. reports total compensation of $3,229,346 for Christopher Frankenfield in fiscal 2025, including a base salary of $533,100. Disclosed compensation is on record for 2 fiscal years. Xilio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Xilio Therapeutics, Inc. includes René Russo (CEO and Board Member), Sara M. Bonstein (Chairman and Board Member), Kevin Brennan (CFO and Chief Accounting Officer) and 7 others.